Press Release November 29, 2021

Blueprint Medicines To Acquire Lengo Therapeutics for $250 Million Upfront and up to $465 Million in Total

The Life Sciences team advised Blueprint Medicines Corporation (NASDAQ: BPMC) on its definitive merger agreement to acquire Lengo Therapeutics, Inc., a precision oncology company, for an upfront payment of $250 million plus up to an additional $215 million based on the achievement of certain regulatory approval and sales-based milestones by Blueprint Medicines. Through this acquisition, Blueprint Medicines will add LNG-451, an oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC) in patients with EGFR exon 20 insertion mutations, and additional undisclosed preclinical precision oncology programs to its pipeline.

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint Medicines has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, it is delivering approved medicines directly to patients in the United States and Europe, and globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

The Goodwin team was led by Danielle Lauzon, Yasin Akbari, Erini Svokos, and Kingsley Taft and included Theresa Kavanaugh, Carolyn Nguyen, Chris Huntsman, Austin Abir, Christopher Zhong, Dillon McDermott, and Elizabeth Caruso (Life Sciences); Paul Jin, Kirby Lewis and Katherine Kissinger (Antitrust); Grace Wirth, Adrean Taylor, and Sebastian Iagrossi (ERISA & Executive Compensation); Jennifer Fay and Caroline Galiatsos (Employment); Robert Kester and Benjamin Gossels (Tax); Susan Lee, Julie Tibbets, and Joe Thomas (FDA); Roger Cohen, Heath Ingram Roosevelt, and Nikhil Sethi (Healthcare); Deborah Birnbach and Katy Dacey (Litigation); and Jacqueline Klosek and Federica De Santis (Data, Privacy & Cybersecurity).

For more details, read the press release and articles in Fierce Biotech, Insider, and MarketWatch.